Frontiers in Aging Neuroscience,
Journal Year:
2023,
Volume and Issue:
15
Published: June 19, 2023
Neurodegenerative
diseases
(NDs)
have
a
slow
onset
and
are
usually
detected
late
during
disease.
NDs
often
difficult
to
cure
due
the
presence
of
blood–brain
barrier
(BBB),
which
makes
it
find
effective
treatments
drugs,
causing
great
stress
financial
burden
families
society.
Currently,
small
extracellular
vesicles
(sEVs)
most
promising
drug
delivery
systems
(DDSs)
for
targeted
molecules
specific
sites
in
brain
as
therapeutic
vehicle
their
low
toxicity,
immunogenicity,
high
stability,
efficiency,
biocompatibility
trans-BBB
functionality.
Here,
we
review
application
sEVs
several
NDs,
including
Alzheimer’s
disease,
Parkinson’s
Huntington’s
discuss
current
barriers
associated
with
brain-targeted
DDS,
suggest
future
research
directions.
ACS Omega,
Journal Year:
2024,
Volume and Issue:
9(33), P. 35223 - 35242
Published: Aug. 5, 2024
Neurodegenerative
diseases,
encompassing
conditions
such
as
Alzheimer's
disease,
Parkinson's
multiple
sclerosis,
amyotrophic
lateral
prion
and
Huntington's
present
a
growing
health
concern
human
life
expectancy
increases.
Despite
this,
effective
treatments
to
halt
disease
progression
remain
elusive
due
various
factors,
including
challenges
in
drug
delivery
across
physiological
barriers
like
the
blood-brain
barrier
patient
compliance
issues
leading
treatment
discontinuation.
In
response,
innovative
approaches
leveraging
noninvasive
techniques
with
higher
are
emerging
promising
alternatives.
This
Review
aims
synthesize
current
options
encountered
managing
neurodegenerative
while
also
exploring
modalities.
Specifically,
strategies
intranasal
administration
nanosized
systems
gaining
prominence
for
their
potential
enhance
efficacy
adherence.
Nanosized
systems,
liposomes,
polymeric
micelles,
nanoparticles,
evaluated
within
context
of
outstanding
studies.
The
advantages
disadvantages
these
discussed,
providing
insights
into
therapeutic
limitations.
Through
this
comprehensive
examination,
contributes
ongoing
discourse
surrounding
development
diseases.
Current Stem Cell Research & Therapy,
Journal Year:
2023,
Volume and Issue:
19(6), P. 852 - 864
Published: July 27, 2023
Extracellular
vesicles
(EVs)
are
one
of
the
crucial
means
intercellular
communication,
which
takes
many
different
forms.
They
heterogeneous,
secreted
by
a
range
cell
types,
and
can
be
generally
classified
into
microvesicles
exosomes
depending
on
their
location
function.
Exosomes
small
EVs
with
diameters
about
30-150
nm
diverse
sources.
Current Opinion in Psychiatry,
Journal Year:
2023,
Volume and Issue:
36(2), P. 119 - 125
Published: Jan. 11, 2023
Dementia
is
a
syndrome
with
several
possible
pathologies.
To
date,
definitive
methods
for
diagnosis
and
treatment
of
sub-types
dementia
have
not
been
established.
Emerging
evidence
suggests
that
exosomes
can
provide
important
information
the
subtypes
dementia.
This
article
reviews
recent
studies
on
application
in
dementia.Exosomes
are
involved
pathogenesis
Alzheimer's
disease
(AD)
Parkinson's
(PD)
through
transporting
toxic
proteins
such
as
amyloid
beta
(Aβ),
tau,
α-synuclein.
Exosomal
microRNAs
(miR)
reflect
state,
therefore,
be
used
diagnostic
markers
diseases
AD,
PD,
Huntington's
(HD),
vascular
(VaD),
Lewy
bodies
(DLB),
frontotemporal
(FTD).
Mesenchymal
stem
cell
(MSC)-derived
shown
to
ameliorate
pathology,
improve
cognitive
function
VAD.Recent
could
novel
agents
because
they
contain
molecules
potential
biomarker
candidates
indicative
type
stage
Therapeutic
has
revealed
only,
or
loaded
an
active
pharmaceutical
ingredient
(API),
phenotype
Further
work
needed
exploit
this
potential.
Frontiers in Aging Neuroscience,
Journal Year:
2023,
Volume and Issue:
15
Published: June 19, 2023
Neurodegenerative
diseases
(NDs)
have
a
slow
onset
and
are
usually
detected
late
during
disease.
NDs
often
difficult
to
cure
due
the
presence
of
blood–brain
barrier
(BBB),
which
makes
it
find
effective
treatments
drugs,
causing
great
stress
financial
burden
families
society.
Currently,
small
extracellular
vesicles
(sEVs)
most
promising
drug
delivery
systems
(DDSs)
for
targeted
molecules
specific
sites
in
brain
as
therapeutic
vehicle
their
low
toxicity,
immunogenicity,
high
stability,
efficiency,
biocompatibility
trans-BBB
functionality.
Here,
we
review
application
sEVs
several
NDs,
including
Alzheimer’s
disease,
Parkinson’s
Huntington’s
discuss
current
barriers
associated
with
brain-targeted
DDS,
suggest
future
research
directions.
